rz geschaeftsbericht teil1...managing director, bavarian biotechnology cluster 07 introduction 09...
TRANSCRIPT
Biotechnologyin Bavaria 2008
3
ImprintEditorial staff: Dr. Georg Kääb, Dr. Petra Burgstaller
Data collection: Dr. Petra Burgstaller, Sabine Jordan
Company Profiles: Ivonne Wagner, Lina Paulenz
Layout-Design: aimcom, Munich, www.aimcom.de
Illustration: dedicated to Charles Darwin in the
“Darwin-Year 2009”
Contact
Prof. Dr. Horst Domdey, Managing Director
Spokesman of the Bavarian Biotechnology Cluster
Nicola Schumacher and Dr. Mathias Lamparter,
Cluster Manager
The Bavarian and the Munich Biotechnology Cluster
are managed by:
BioM Biotech Cluster Development GmbH
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0)89-89 96 79-0
Fax: +49 (0)89-89 96 79-79
E-Mail: [email protected]
Internet: www.bio-m.org
The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.
4
ContentWelcome notes/Preface 06-07
Martin Zeil – Bavarian Minister of Economic Affairs,
Infrastructure, Transport and Technology 06
Prof. Dr. Horst Domdey –
Managing Director, Bavarian Biotechnology Cluster 07
Introduction 09
The Companies in the Bavarian Biotechnology Cluster 11-12
Current Status 11-12
Employment 13
Jobs in biotechnology companies 13
The Bavarian Biotech SMEs 14
More about Employment 14
Products and Pipeline 15
Drug development 15
Deals, Cooperations, Mergers, Financing 17-19
Big Deals and Cooperations 17
M&A Activities in Bavaria’s Biotechnology Sector 18
Financing 18
Revenues 19
Summary 19
Portaits of Research Cooperation Networks in Bavaria 20-29
Network IBP – industrial „white“ Biotechnology 20
BayGene – The Bavarian Genome Research Network 22-23
BayImmuNet – Bavarian Immunotherapy Network 24-25
ForNeuroCell – research on adult neural stem cells 26-27
ForZebRA – New Stem Cell Research for the aged 28-29
Company profiles 31-115
in alphabetical order
5
Bavaria has been pursuing a sustainable policy of innova-
tion for many years now and has consistently invested in
research and technology. The excellent Bavarian research
institutions are like a spring constantly bubbling over
with innovative ideas, which makes them an ideal breeding
ground for the biotech sector. But transforming highly
promising ideas into successful products calls for an effec-
tive technology transfer process. This is where our clusters
are making an important contribution – by encouraging
the exchange of know-how between research institutes
and companies, speeding up interdisciplinary knowledge
transfer and establishing contacts for future cooperation
projects.
Framework conditions such as tax law and public health are
also key factors playing an important role in the development
of Bavaria’s biotech industry. Tax incentives for external
equity providers are needed, if we are to continue building
up ambitious high-tech companies in Bavaria also in the
future. Although the situation in the VC market in Germany
did improve slightly last year – at € 570 million 22 percent
more was invested in all branches than in the year before –
it is highly unlikely that we will be able to maintain this level
in 2009. Moreover, the gulf separating us from the USA is
still very wide.
6
Welcome Note for the BiotechnologyReport 2008 of the Biotechnology Cluster
MARTIN ZEILBavarian State Minister of
Economic Affairs, Infrastructure,Transport and Technology
In 2008, one quarter of all German VC investments were
made in Bavaria. This is no mere coincidence: for years,
Bavaria has been pursuing a strategy of boosting private
equity investments with government funds provided by
Bayern Kapital GmbH. In order to help young high-tech
firms overcome their shortage of capital in the current
financial crisis, the € 30 million ‘Clusterfonds Innovation’
programme was launched in March 2009 and can provide
up to € 2 million for companies in the seed and start-up
phase. Further-more, the LfA Bank for the Advancement of
the Bavarian Economy and the EIF European Investment
Fund offer assistance to VC management teams based in
Bavaria within the scope of the umbrella fund initiative to
be launched early in May 2009, which is worth € 50 million.
Despite the economic downturn that was already reaching
serious proportions at the end of last year, the present
report shows that 2008 was a successful year for Bavarian
biotechnology. This is an extremely pleasing result confirming
our policy of past years. We are not, however, going to sit
back and enjoy this success, but will continue to invest in
enhancing biotechnology in Bavaria with the “BayernFIT“
Initiative: the third construction phase of the BioPark
Regensburg, two Fraunhofer project groups (“Chemical and
Biosensor Technology” in Regensburg and “Biogenous
Resources” in Straubing), the promotion of new projects in
the field of “white biotechnology”, the Dementia Research
Centre in Munich-Grosshadern and the construction of a
new Biomedical Center in Martinsried are just a few examples.
These measures will contribute to making Bavaria one of the
leading biotechnology locations in Germany, Europe and
worldwide in the future as well.
“Evolution by Innovation” is the slogan we have selected
for this year’s Annual Report of the Bavarian Biotechnology
Industry. This title is – of course – intended to be a tribute
to Charles Darwin who is celebrated this year for at least
two reasons: 2009 is the 200th anniversary of Charles
Darwin’s birthday and it is also the 150th anniversary of
the first publication of his famous book “On the Origin of
Species”, which marks the beginning of the evolutionary
theory.
You may ask: What has Bavaria and what has biotechnology
to do with Darwin or his theory of evolution? It is by no
means our intention to deprive the British of their Darwin,
but we would nevertheless like to adopt the term evolution
for an industry which is as young as modern biotechnology.
Evolution is incidentally also a theme that is currently
undergoing a renaissance – highly topical in days which are
shaped by the global financial and economic crisis:
7
Preface
PROF. DR.HORST DOMDEY
Managing Director, BavarianBiotechnology Cluster
Companies are established, they evolve and develop the most
intricate networks of connections, both inside and outside
their own economic niches, they adapt their business models
to changing economic framework conditions and, if they fail
to adapt to the changes in the business world, they disappear.
This “play of forces” has existed ever since the ancestors of
contemporary man began using a system of barter for their
first trading activities. To many of us it came as a surprise to
discover that banks, big corporations and even whole states
were beginning to drift into insolvency – or were being dri-
ven into it – by a simultaneous world economic crisis, or
could only be saved using the greatest efforts and through
governmental interventions.
But there are also ecological niches in this global economy –
which brings us back to the biotechnology sector, and espe-
cially to the one in Bavaria. In this specific environment –
Biotech in Bavaria – the focus is very much on innovation and
the search for niches for a new product, a new technology, a
new company. What – in evolutionary terms – is the undirec-
ted mutation, is – in business terms – the “crazy idea” aiming
at a true innovation.
What we really need in this evolutionary process is sufficient
space and a flexible environment for the mutations/ideas
and their resulting innovations. If the right environment is
provided, Bavaria’s biotechnology will not only survive but
will even have a good chance to arise strengthened from
the current dreadful overall crash.
8
A Tribute to
9
It is just twenty years since the evolutionary process – the
creation of innovative and marketable products starting
from and with “crazy ideas” – began in Bavaria´s biotech-
nology sector, from the time when the first companies of
this type were created and established here.
In these past twenty years, the creation, occupation and
defence of a new niche in the health care market – that’s
what most of the Bavarian companies are aiming for – has
passed through all the chapters in Darwin’s book "On the
Origin of Species", from adaptation via selection to the survi-
val of the fittest.
And it is these very “survivors” that are the subject of this
annual report based on a detailed survey of all companies
in the Free State carried out by BioM Biotech Cluster Devel-
opment GmbH. To do this, we distinguished the parameters
specific to each sector and conducted separate surveys for
biotech companies, pharmaceutical companies, contract
research organizations (CROs), contract manufacturing
organizations (CMOs), suppliers and others with activities in
the biotechnology sector. In the case of the biotech
companies, a distinction was once again made between
small and medium-sized companies (SME) having their
headquarters in Bavaria and branch offices and subsidiaries
of national and international biotech companies (biotech-
nology companies, non-SMEs). The term “non-SME” therefore
says nothing about the actual size of this branch office.
For the following report, a biotechnology company has been
defined as a company, which develops and/or manufactures
products on the basis of state-of-the-art molecular biological
methods. But as “conventional” pharmaceutical companies
are increasingly also using such methods, it is often difficult
to differentiate between biotech and pharma. Traditional
phytopharmaceutical companies and manufacturers of
homeopathic products are however not included in this
compilation.
The data forming the basis of this report are based on the
evaluation of a written survey carried out by BioM Biotech
Cluster Development GmbH at the beginning of 2009 of
approx. 320 Life Science companies throughout Bavaria.
Based on the questionnaires returned and intensive followup
telephone calls it was possible to achieve a response rate of
almost 65%.
Additional information was obtained by further individual
investigations. Possible deviations from previously published
figures are the result of additional data obtained in this
survey that also refer to the previous year. The period under
review for this report is the year 2008. Data used in this
report that are not a result of the survey come from other
sources that are mentioned separately on the respective
pages.
Guest articles present current Bavarian research networks
between university and industry. A detailed description of
Bavaria’s Life Science companies provides the reader with all
necessary information about their scope of business and
contact data.
April 2009
Introduction
10
Current Status
Below, we present the results of the company survey
carried out at the end of 2008/beginning of 2009. We look
back at 2008, a year when a crisis in the American real
estate sector developed into a financial crisis with global
impact and now into an outright world economic crisis.
No-one could possibly have foreseen this evolutionary
process, caused only by bad (“subprime”) real estate loans
in the USA. Last year, however, the health industry, i.e.
both the pharmaceutical and the biotechnology sectors,
was still relatively unaffected by this crisis, and indeed,
one could even assume it got off lightly.
With this proviso in mind, namely whether looking at the
past in today’s “troubled times” can also actually say some-
thing about the future, we shall do exactly that: we shall look
back at 2008 as being a very successful year for Bavarian
biotechnology, despite all the growing mood of crisis.
Biotech SMEs and non-SMEs:
In 2008, there were 164 active biotech SMEs in the whole of
Bavaria. 118 of these SME biotech firms are domiciled in the
Munich conurbation, in addition 18 non-SME biotech com-
panies can be found in the Greater Munich Area.
Regensburg on the Danube has the second-largest company
cluster in Bavaria, with 22 biotech companies (SMEs and
non-SMEs) and additionally some 18 companies working in
MedTech, biomaterials and other fields like industrial bio-
technology.
11
The Companies in the BavarianBiotechnology Cluster
Biotech companies(SMEs)
Biotech companies(non-SMEs)
CROs
Pharma companies
Suppliers/CMOs
156157164
number of companies 20 40 60 80 100 120 140 160
2006 (total: 301) 2007 (total: 305) 2008 (total: 319)
BIOTECH/PHARMA COMPANIES IN BAVARIA
There were 15 newly established companies in total (14 in
and around Munich, 1 in Northern Bavaria) and 8 close-
downs. What is particularly striking is the clear increase in
the number of newly established companies compared with
previous years (2006: 4; 2007: 10). But a trend already obser-
ved in recent years is nevertheless continuing: most of the
newly established companies are providing services on the
basis of platform technologies or specific know-how; appa-
rently there are hardly any pure “drug” companies being
established any more; companies are tending to need to
“earn money” straight away, rather than resorting to finan-
cing over the first few years of development. The business
model practised in the biotech sector is therefore increasin-
gly resembling those used in other sectors. For business
ideas irrefutably requiring seed financing, because no other
revenue can be generated, the situation is still difficult even
in Bavaria.
252729
545759
363435
303032
COMPANY CATEGORY ORIGIN
AMSilk GmbH Agriculture, Food, Tech. UniversityEnvironment of Munich (TUM)
AmVac Research GmbH Therapeutics & Diagnostics company spin-off
Baseclick GmbH Devices/Reagents University of Munich (LMU)
BayGenetics Agriculture, Food, University of Environment Bayreuth
BioEPS GmbH Services company spin-off
CellTool GmbH Devices/Reagents n.d.
ChromoTek GmbH Devices/Reagents University of Munich (LMU)
Coriolis Pharma GmbH Preclinical Services University of Munich (LMU)
Intana Bioscience GmbH Preclinical Services company spin-off
MWM Biomodels GmbH Preclinical Services University of Munich (LMU)
NanoTemper GmbH Devices/Reagents University ofMunich (LMU)
Nomad Bioscience GmbH Agriculture, Food, company spin-offEnvironment
OncoLead GmbH & Co. KG Therapeutics & Diagnostics company spin-off
Proteros fragments GmbH Devices/Reagents company spin-off
SiNatur GmbH Therapeutics & Diagnostics company spin-off
COMPANY FOUNDATIONS
12
To stay with the biotech SMEs, the next chart shows the
distribution of specialisations, the fields of business, on
which individual firms have decided to concentrate. The two
main fields of business of these firms in Bavaria are the
development of therapeutics/diagnostics (67 companies)
and the manufacture of devices and reagents (53 companies).
It is therefore not surprising that most people are also
employed in these sectors (see following chapter). More
explicit descriptions of the profiles of these and all the other
Bavarian Life Science companies can be found in the exten-
sive Appendix (s. pages 31f ).
Besides the SMEs, there are 29 branch offices and subsidiaries
of national and international biotechnology companies
(non-SME biotech). The term “non-SME” therefore says
nothing about the actual size of this branch office. One of
these companies for example is Roche Diagnostics in
Penzberg south of Munich. In the ten years since it took over
the Penzberg site in 1998, the Swiss parent company Roche
has invested over € 1.5 billion in new plant and doubled its
work force to over 4,400 employees. In the internal competi-
tions for these investments, Penzberg regularly held its own
against international Roche sites in the USA and Asia:
Penzberg has now established itself as a strategic “centre of
excellence in therapeutic proteins” within the group.
CROs and Pharma:
There are 2 new additions to the group of contract research
organisations (CROs, 59 in 2008), and nearly the same number
of pharmaceutical companies remain as in 2007 (+1). These
companies contribute significantly to the number of
LifeSciences staff in full-time employment, the CROs having
the highest increase in employees of all the categories inve-
stigated (see next chapter).
CMOs, Suppliers, others:
When looking at companies relevant to the biotech industry
from a more general point of view, we must include suppliers,
contract manufacturing organizations (CMOs) and a few
other companies doing contract research. We therefore
included these 32 companies in this survey.
In the field of white or industrial biotechnology, Wacker and
Süd Chemie are two major “global players” operating in
Bavaria. These companies intend to adapt their chemical pro-
duction processes to bring them more into line with biotech-
nological methods and are investing heavily in research and
development with this in mind. Moreover, they are engaged
in networks between science and universities such as the
Bavarian White Biotechnology Network (IBP, see page 20).
There are also 8 biogas companies in Bavaria employing
about 600 persons. These companies however focus rather
on the construction of biogas plants than on biotechnology.
For these reasons biogas companies and the big chemical
companies with only a sideline activity in industrial biotech-
nology are not further included in this survey or in the figures.67
16
8
53
13
7
number of companies 10 20 30 40 50 60
BAVARIAN BIOTECH SMES IN 2008
Therapeutics/ Diagnostics
Agriculture, Food, Environment
Bioinformatics
Devices/Reagents
DNA-/Protein-Analysis
Preclinical Services
13
Employment
Jobs in biotechnology companies
Compared with the previous year, the number of people
employed in all biotechnology companies has risen by 300
to about 8.800 (+ 3,5%). Bavarian biotech SMEs alone cur-
rently employ 3.210 people (previous year: 3.070; +4.6%)
of which around 2.630 work in the greater Munich area.
At the end of 2008, there were 1.040 people employed in
the biotechnology sector in the Regensburg region
(in 2007 it was 895).
In addition to the 3.210 employees in the small and medium-
sized biotechnology companies there are almost 5.610
people working in the branches and subsidiaries of interna-
tional biotechnology companies; nearly 4.470 alone are
working for Roche in Penzberg. In addition, there are a good
9.000 employees working for national and international
pharmaceutical companies. Apart from this, a not inconsid-
erable percentage of local Life Science jobs are offered by
CROs. Approximately another 1.900 people are employed in
this sector. If one looks back a few more years in the deve-
lopment of the CROs in Bavaria, it is quite striking that these
roughly 60 companies have increased their staff numbers
since 2006 by over 20%.
A significant contribution to employment and economic
strength is also made by the “other companies”, which include
suppliers and other service companies as well as production
plants (CMOs), where some 1.920 people are employed.
The total number of employees in the Bavarian Life Science
industry in 2008 came to around 22.000. But this is still not
the full picture, as it does not include the specialised
consulting, finance, patent, marketing and communications
companies, which nevertheless play a very important role in
the development of the corporate landscape and thus of
Bavaria as a top business location.
Biotech (SMEs)
Biotech (non-SMEs)
CROs
Pharma
Suppliers
3.210
5.610
1.900
9.040
1.920
NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER
14
Biotech companies(SMEs)
Biotech companies(non-SMEs)
number of employees 2.000 4.000 6.000
2006 2007 2008
DEVELOPMENT OF STAFF NUMBERS INBIOTECH COMPANIES
2.9103.0703.210
5.1705.4505.610
1-10 Employees
11-50 Employees
51-100 Employees
101-250 Employees
61%
27%
6%
6%
SIZE OF BIOTECH SMES BY NUMBEROF EMPLOYEES IN 2008
The Bavarian Biotech SMEs
More about Employment
Looking at the Biotech SMEs in Bavaria, it is very clear that
they focus on the development and marketing of therapeutic
and diagnostic products. Nearly two thirds of the 3.210
employees are working in this area. The other strong focus is
developing of devices and reagents where nearly 800 persons
are employed.
Although the first Bavarian biotech company started twenty
years ago, and by 1996 already 30 companies had been
founded, many of the Bavarian biotech SMEs are less than
10 years old. This youth of many companies can also be seen
in the size of the Bavarian SMEs.
While most of the Bavarian Biotech companies employ
between 1-50 staff members (88% of the SMEs), the majority of
biotech employees work for the 19 greater companies with
staff numbers over 50 (58% of total employees).
The positive development of the staff numbers in the last
few years is shown in a separat figure.
1.887
140
177
764
137
103
number of employees 0 200 400 600 800 1.000 1.200 1.400 1.600 1.800
NUMBER OF EMPLOYEES IN THE BIOTECH SMES IN BAVARIA (2008)
Therapeutics/ Diagnostics
Agriculture, Food, Environment
Bioinformatics
Devices/Reagents
DNA-/Protein-Analysis
Preclinical Services
15
Drug development
Bavaria continues to live up to its leading role in drug deve-
lopment in Germany. In 2003, MediGene from Martinsried
was the company to receive the very first approval for a
drug developed by a German biotech company. In the years
following, MediGene again got approval for 2 more pro-
ducts, which means that, by the end of the year 2008, there
were 3 approved “Bavarian drugs” and 1 further drug in the
final phase of the approval process.
Now, in April 2009, EMEA has approved this drug:
it being the innovative proprietary development of a “tri-
functional antibody” from the Munich based TRION Pharma
company – together with Fresenius Biotech. In other words,
there are by now 4 approved drugs developed by Bavarian
biotechnology companies all originating from the Munich-
Martinsried region, the centre of the Bavarian Biotech
Cluster.
At present (April 2009), clinical development programmes
of the Bavarian SMEs deal with the fields of indication listed
in more detail below.
4SC: Rheumatoid ArthritisAffectis: DepressionAntisense Pharma: GlioblastomaAvontec: Asthma, PsoriasisBavarian Nordic: SmallpoxDoNatur: k.A.IDEA: Onychomycosis, Skin pain and InflammationMediGene: Pancreatic Cancer, Breast Cancer,Rheumatoid Arthritis Micromet: Prostate Cancer, Breast Cancer,Acute Lymphoblastic LeukemiaMorphoSys (with Centocor): ImmunologyScil: Periodontitis Fresenius Biotech/ TRION Pharma: Breast CancerVasopharm: Closed Head InjuryWilex: Pancreatic Cancer, Breast Cancer
Curacyte: Hemoximer®, SepsisDoNatur: MCS-18, PeriarthritisGPC Biotech: Satraplatin®, Prostate Cancer IDEA: Diractin®, OsteoarthritisWilex: Redectane®, PET-ImagingWilex: Rencarex®, Kidney Cancer
MediGene: Eligard®,Prostate Cancer (Europe)MediGene: Veregen®,Genital Warts (USA)MediGene: Oracea™,Rosacea (Europe, sold) Fresenius Biotech/TRION Pharma:Removab®, Malignant Ascites(Europe)
number of drug candidates
100
90
80
70
60
50
40
30
20
10
0
DRUG PIPELINE IN BAVARIA
Preclinic Phase I Phase II Phase III Approved
95
19 19
64
PHA
SE II
PHA
SE II
I
APP
ROVE
D
Products and Pipeline
16
Type of Cooperation
Pfizer and Scil finalize agreement for novel cartilage growth factor
KINAXO Biotechnologies Enters Agreement with Takeda
The US National Cancer Institute Extends its Contract with GENEART – OrderVolume USD 1.9 M
Medtronic and Scil Technology Establish Partnership for Dental BoneRegeneration Therapies
QIAGEN and GENEART Partner to Commercialize Synthetic Mammalian Genes
4SC to acquire Nycomed oncology projects
WILEX and IBA enter into worldwide marketing, distribution and sales agreementon REDECTANE® (CA9-SCAN)
MediGene Sells Licensee Rights to the Drug Oracea® to Galderma
MorphoSys and Galapagos Enter Alliance to Co-develop Novel TherapeuticAntibodies in Bone and Joint Disease
Development of Diabetes II drug leads to € 318 mio in milestone payments
Announcement of Cooperation
Jan 08
Apr 08
Apr 08
Apr 08
May 08
Jun 08
Jun 08
Jul 08
Nov 08
Dec 08
Cooperation Partner
Pfizer
Takeda
National Cancer Institute
Medtronic
Qiagen
Nycomed
IBA
Galderma
Galapagos
Astra Zeneca
COOPERATIONS AND DEALS 2008
17
Big Deals and Cooperations
It is this product pipeline and the excellent technology
platforms that make Bavarian biotechnology companies
especially attractive to national and international part-
ners from industry.
After MorphoSys AG from Martinsried surprised everybody
at the end of 2007 with the megadeal with Novartis (under
which at least € 400 million will flow to Morphosys from
Switzerland in the next ten years), and Idea AG succeeded
in concluding an attractive licence agreement with Alpharma
for over € 124 million, the year 2008 also began with some
positive news.
At the beginning of 2008, Scil Technology in Martinsried was
then also able to report two big deals: Pharmaceutical giant
Pfizer is prepared to pay around € 190 million if the further,
now joint, product developments go according to plan. And
Medtronic, another giant in the field of medical technology,
has entered into a development-collaboration agreement of
an almost similar size with Scil, although they have agreed
not to disclose the financial terms.
Deals, Cooperations, Mergers, Financing
Early in 2008, MediGene received approval for “Oracea”, and
a few months later sold the marketing licence to Galderma
obtaining for its drug a possible total volume of € 32
million.
Along with its close alliance with Novartis, MorphoSys has
been able to develop many more partnerships, for example
with Astellas, Sigma Aldrich, Schering-Plough and Daiichi
Sankyo as well as entering into new ones, for example with
Galapagos from Belgium which was published late in
December 2008 (see some of all the deals and cooperations
in the listing).
The announcement of another “big deal” came in late
December from the North West of Bavaria: the company
Cellmed in Alzenau managed to attract AstraZeneca in a
strategic partnership in the diabetes and obesity field,
worth up to € 320 million at least.
The magnitude of all these deals exceeds by far all other
financing volumes as is described in the next chapter.
MBC Firma/Bayer. Firma
Scil
Kinaxo
Geneart
Scil
Geneart
4SC
Wilex
MediGene
MorphoSys AG
Cellmed AG
18
Mio. €
600
500
400
300
200
100
0
EXTERNAL FINANCING AND DEALS
2006 2007
Follow-OnIPOVC + Silent PartnershipsFinancing “on demand”closed deals (dotted line)in the respective year only
151,4
76,7
78,2
42,2
139,6
34
533
2008
84,0
57,2
61,2
540
Financing
Successful financing rounds were completed by Freising’s
Pieris (€ 25 million), Suppremol (€ 16 million) and Corimmun
(€ 5 million), all from Martinsried. And some publicly listed
companies from Martinsried actually even managed to
increase their capital in 2008, namely 4SC (€ 30 million) and
Micromet (€ 30 million).
Virologik of Erlangen acquired financing of € 7 million,
and many got seed funds in the 6 to 7-digit range such as
Sirion and Lophius. Interestingly, the companies doubled
the volume of support funding (grants) provided from
governmental or federal sources to € 16 million compared
with 2007.
If all the financing is taken together, a total of around € 120
million is obtained for the Bavarian biotech companies, which
is not much these days, when everyone is calling for one
hundred billion dollar rescue packages, but it is not too bad
in the present so-called “real economy”. VC-investments in
LifeSciences in Germany account for about € 140 million in
2008 (BVK, German Private Equity and Venture Capital
Association) nearly half of it went into Bavarian companies.
Two companies from Martinsried managed to open a new
chapter in financing models: namely “financing on demand”.
Micromet has been promised funds of nearly € 60 million,
whenever the companies thinks it might need them.
MediGene managed to secure itself € 25 million under this
“financing on demand” model.
In spring 2008, Till Photonics from Gräfelfing near Munich, a
company whose core competence is molecular imaging, was
taken over by Agilent Technologies. And the biotech compa-
ny U3 Pharma, Martinsried, was taken over by Japan’s third
largest pharmaceutical company Daiichi Sankyo for around
€ 150 million.
The two takeovers are having very positive effects on the
location: the companies’ know-how has not simply been
“sold off ”, because the two big corporations are determined
to establish a base in and close to the Martinsried biotech-
nology centre in this way. This means that the companies
and their know-how will remain at the location and will
definitely be developed further by their new parent group.
And Bavarian companies themselves have been active in
gaining a foothold: 4SC of Martinsried bought 4% of Nexigen
(Bonn, Germany) with the option of a complete takeover.
M&A Activities in Bavaria’s Biotechnology Sector
The Bavarian biotechnology industry is also proving to be attractive to international companies on the lookout for reasona-
ble supplements to their portfolio. In 2008, two companies from Munich’s south attracted the attention of company scouts,
ultimately leading to company takeovers:
19
161 192
2006
REVENUES TOTAL IN MIO. €, LISTED COMPANIES
Summary
The Bavarian biotech industry can look back on a history
that has developed over just two decades, a history with
more ups than downs.
Within this period of about 20 years – in evolutionary time-
scales not even a blink of an eye –, an industry employing
around 9.000 people (21.000 including pharma and suppliers)
has established itself and has been able to build up a
tightly-knit network of interrelationships, not only within
itself, but also at international level. Despite the most adverse
conditions in 2008, a year of crisis, these companies have
shown remarkable stability and even positive developments.
If it was possible to look at the biotechnology industry in
isolation ignoring all the surrounding sectors, then there
would certainly be no question of a crisis here. However, it is
perfectly possible that even economic niches might be hit
by the offshoots of the waves of crisis spreading like a
tsunami – and Bavarian biotechnology companies could yet
be struck by a new evolutionary challenge.
But the Bavarian biotech companies seem to be able to
deal successfully with any difficult times the future may
hold in store - according to our slogan:
evolution by innovation!
2008
2007
154
Revenues
For comparison, the figure on the right focus on the
published business data of Bavarian biotechnology com-
panies quoted on the stock exchange.
These are:
4SC, Geneart, GPC, MediGene, Micromet, MorphoSys, MWG
and Wilex.
Their stated sales revenues for 2007 accounted for € 154
million and add up for 2008 to € 192 million, which is a plus
of nearly 20%. The R&D investments by these listed compa-
nies total € 144 million.
62% of all the other biotech SMEs answered our question-
naire concerning their revenues. It reveals about € 150 million
in total revenues and € 110 million for R&D investments.
The real picture of all the revenues the Bavarian Biotech
SMEs account for in 2008 will therefore approximatly sum
up to between € 350 to € 450 million.
20
Network White Biotechnology
The Network IBP (“Industrial Processes with Biogenic Buil-
ding Blocks and Performance Proteins”) is a winner of the
competition “BioIndustry 2021” of the Federal Ministry of
Education and Research (BMBF). It is a consortium of
academic and industrial partner who brought together
their complementary skills to develop new processes and
products in the sector of White Biotechnology.
IBP’s focus is manufacturing of chemicals from renewable
feedstock by using novel implementation strategies. To this
end, complex lignocellulosic material is decomposed by a
unique method called “sequential enzymatic hydrolysis”
(“SEH”), which avoids problems usually associated with total
hydrolysis, like heterogeneous mixtures of plant components.
By this process, the feedstock is supposed to yield rather
pure biogenic building blocks. These are further refined to
products, like acetate or ethanol, by efficient methods like
anaerobic fermentation, metabolic engineering and
“in process chemistry”. The conversion and separation of the
substances occur via “performance proteins”, e. g. technical
enzymes. The Network IBP strivers to exploit the entire plant
material like lignin, proteins and secondary metabolites –
not just carbohydrates.
By its concept, the Network IBP will demonstrate an economic
production of hitherto only petro-chemically manufactured
biogenic building blocks and basic chemicals. Moreover,
IBP establishes a sustainable “3rd generation” biorefinery:
There is no competition with food resources and fewer
impurities of intermediates and products may be expected.
IBP creates value through production-embedded measures
for the protection of the environment, as opposed to
aftercare. These benefits result in clear economic advantages
and increase of performance and competitiveness of the
participating network partners. IBP supports the development
of White Biotechnology from a niche technology to an
economically and ecologically efficient platform technology
for the chemical industry.
Portaits of Research Cooperation Networks in Bavaria
Network White Biotechnology
For its technical projects, IBP gains a subsidy of € 10 million
from BMBF and the Ministry of Economic Affairs, Infrastruc-
ture, Transport and Technology of the Free State of Bavaria.
This amount is doubled by the industry.
For the administrative management of the Network IBP and
for the more general challenge to strengthen White
Biotechnology, BioM WB GmbH was founded in June 2008 by
the “Association for the Promotion of White Biotechnology in
Bavaria”. BioM WB GmbH pursues the establishment of an
international network of White Biotechnology centred in
Bavaria. The company is funded by the Ministry of Economic
Affairs, Infrastructure, Transport and Technology of the Free
State of Bavaria, by the Federal Ministry of Education and
Research (BMBF) as well as by the globally operating chemical
companies Wacker Chemie AG and Süd-Chemie AG.
BioM WB GmbH works closely with the Bavarian Biotech-
nology Cluster and supports the “Cluster-Initiative” of the
Bavarian Government.
The concept of research cooperations for interdisciplinary and close to application research projects has a long tradition in
Bavaria. In the last twenty years there were more than ten specific research cooperations in the LifeSciences coordinated by
the Bavarian Research Alliance. Two of the still running programs you can find in the latter part of this survey (ForNeuroCell
and ForZeBRA). But there are also other main research cooperation projects that are seperatly managed, of these we present
the “White Biotechnology”, the Bavarian Genome Research and the Bavarian Immunotherapy Networks on the next pages.
CONTACT
BioM WB GmbH
Prof. Dr. Haralabos Zorbas
CEO and Spokesman of Network IBP, IZB West
Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0)89-54 04 54 714
Fax: +49 (0)89-54 04 54 715
E-Mail: [email protected]
Internet: www.biom-wb.com
21
22
For these reasons, the Bavarian State Ministry of Sciences,
Research and the Arts provided € 27 million in total for
seven years to set the starting signal for the foundation of a
unique network, which is intended to support outstanding
academic research in the field of functional genome research.
Initially, five projects met the standards of excellence set by
an international scientific advisory board and, subsequently,
received funding for seven years. An additional four projects
were selected in 2006. Since then, financial support of one
of the nine BayGene projects has ceased, but the project
enjoys continued membership status. Three new projects
were selected in February 2009 and are expected to receive
funding for a period of five years starting in May 2009.
Scientific Projects
Molecular pathogenesis of hereditary cerebrovascular
malformations of the central nervous system
Prof. Dr. Ute Felbor, University Würzburg
Functional genomics of herpes viruses: Identification of
pathogen-specific events by systems biology-based
approaches
Prof. Dr. Dr. Jürgen Haas, LMU München
Regulatory networks of intracellular membrane modula-
tion: Signalling complexes of the Spir actin nucleation
factors and the RasGEF very-KIND
Prof. Dr. Eugen Kerkhoff, University of Regensburg
Functional genomics and therapy of early-disseminated
tumor cells: A novel approach to the prevention of meta-
stasis
Prof. Dr. Christoph Klein, University of Regensburg
Molecular mechanisms of chromatin dynamics
Prof. Dr. Gernot Längst, University of Regensburg
Experimental characterization of micro RNA- interaction
networks
Dr. Gunter Meister, Max-Planck-Institute for Biochemy,
Martinsried
BayGene –The Bavarian Genome Research Network
Genetic protein folding defects: Development of
pharmacotherapeutic strategies
Prof. Dr. Ania Muntau, LMU München
Antibody mediated effector function and control
mechanisms for B-cell tolerance in the humanised mouse
Prof. Dr. Falk Nimmerjahn, University Erlangen-Nürnberg
Functional genomics of degenerative, metabolic, and
malign diseases
Prof. Dr. Peter J. Oefner, University of Regensburg
(Senior Project)
Modelling signal transduction networks and their impaired
function in malignant tumours
Prof. Dr. Rainer Spang, University of Regensburg
Molecular imaging: An instrument for functional proteomics
Prof. Dr. Hans Jürgen Wester, TU München
The Bavarian Genome Research Network faces up to the
challenges of this promising area: outstanding research pro-
jects in the domain of genome research are supported and
cooperate amongst each other using this newly created net-
work BayGene. To realize their visions, aims and strategies,
scientists will coordinate their efforts crossing local bounda-
ries in this pan-Bavarian network to increase the efficiency
and flexibility of their research and to achieve its goals
faster.
Summary of Achievements
The members of the BayGene program have filed seven
patent applications and published a total of 120 papers since
the beginning of funding. Of the publications, 38 appeared
in scientific journals rated with an impact factor >10, amongst
them the Annual Reviews of Immunology, Nature, Nature
Reviews Immunology, Nature Cell Biology, Science and
Cancer Cell. In addition to their BayGene funding, the net-
work’s projects received an additional € 14.8 million in fun-
ding from other grants. These achievements, a market
authorisation of a drug and the formation of a start-up
The Bavarian Genome Research Network coordinates leading research projects in the field of functional genome research in
Bavaria. Based on a better understanding of gene functions, interactions and regulatory mechanisms, significant progress
can be expected in the diagnosis and treatment of illnesses such as cancer and diabetes. The scientific and economic possibi-
lities of functional genome research will significantly change industry and society in the 21st century.
23
CONTACT
BayGene Gene Center Munich
Main Office: Dr. Ulrike Kaltenhauser
Feodor-Lynen-Str. 25
D-81377 Munich
Phone: +49 (0)89-8 59 50 54
Fax: +49 (0)89-85 66 16 80
E-Mail: [email protected]
Internet: www.baygene.de
company justify impressively the investment made by the
Bavarian State Ministry of Sciences, Research and the Arts
into cutting-edge genome research. Integration of regional
industries into the network structure is one of BayGene's
aims. For this reason, eleven Bavarian biotechnology compa-
nies are affiliated with BayGene.
This research effort initiated and funded by the Bavarian
Government is an important step in maintaining Bavaria’s
leading position in the national economic and international
scientific competition.
Scientific advisory board:
Chairman: Professor Dr. Fritz Melchers, Berlin
Members:
Dr. Carmen Buchrieser, Paris
Professor Dr. Manfred Dierich, Innsbruck
Professor Dr. Lutz Gissmann, Heidelberg
Professor Dr. Michael Hallek, Cologne
Professor Dr. Jürgen Hescheler, Cologne
Professor Dr. Lukas Huber, Innsbruck
Professor Dr. Mathias Müller, Vienna
Professor Dr. Sabine Werner, Zurich
Scientific director:
Professor Dr. Horst Domdey,
Martinsried
Managing director:
Dr. Ulrike Kaltenhauser,
Munich
24
Who we are
BayImmuNet is a Bavaria-wide research network that is
focused on the translation of innovative immunotherapeutic
strategies into early clinical trials. Network members are
scientists and research groups at the five Bavarian universities
with medical faculties that perform translational research
projects within BayImmunNet. Network partners are phar-
maceutical and biotech companies interested in novel
immunotherapies. BayImmuNet and its projects are suppor-
ted by the Bavarian State Government within the “BayernFIT”
programme, up to a total of € 10 million. The five participa-
ting universities contribute up to € 4 million. Currently sup-
ported research projects explore novel therapies in trans-
plantation medicine, cancer treatment and auto immune
diseases.
AIMS
Our motto is: „Collaborate in research! Share knowledge!
Conquer disease!“ Thus, it is our common goal to…
intensify the collaboration of academic centres and to
promote partnerships with pharmaceutical and biotech
companies.
accelerate the transfer of research findings into early
clinical trials (“translational medicine”).
develop therapeutic reagents suited for clinical
applications.
Areas of activity
We support renowned scientists in the field of translational
immunotherapy in Bavaria by financing research groups.
We provide financial support for talented young scientists
who contribute to the development of new therapies.
We facilitate collaborations between scientists and research
centres in Bavaria through the exchange of know-how and
technologies, joint clinical studies, open access to specialized
laboratory facilities, etc. We promote joint ventures between
science and business to accelerate the transfer of research
findings into clinical practice on the basis of mutual coope-
ration agreements.
Projects
Funding by the Free State of Bavaria enables BayImmuNet to
support…
five research groups at the university hospitals in
Erlangen, Munich, Regensburg and Würzburg
preclinical and clinical trials to develop and apply new
immunotherapeutic agents
the "José Carreras Centre for Somatic Cell Therapy"
(GMP facility) at the Regensburg University Hospital.
All projects are assessed by an independent scientific advi-
sory committee and supported and supervised by a co-ordi-
nating committee.
BayImmuNet’s “Translationalimmunotherapy” project teams
In September 2008, five “translational immunotherapy”
project teams started their work studying immunotherapy
approaches in the fight against tumour diseases and infections.
Project team at the Erlangen University Hospital:
“Adoptive T-cell Therapy for the Treatment of Patients with
Cancer”. This project aims to develop new strategies for the
priming, selection and expansion of antigen-specific effector
T cells under the guidelines of good manufacturing procedure
(GMP) that will be used for adoptive T-cell therapy in patients
with solid and hematologic malignancies.
Project management: Professor Dr. med. Andreas Mackensen
Project team at the Munich University Hospital (Grosshadern):
“Immunotherapy of high-risk acute myeloid leukaemia using
dendritic cell vaccination”. The central goal of this project is
to develop a multiplex DC vaccine for immunotherapy of
AML and to implement a clinical phase I/II study in
high-risk patients. The vaccine will utilize RNA-pul-
sed mature dendritic cells that have the capacity
to secrete bio-logically active IL-12p70, in order
to activate both Th1-polarized adaptive and
innate immune responses.
Project management:
PD Dr. med. Marion Subklewe
BayImmuNet –Bavarian Immunotherapy Network
25
Project team at the Munich Technical University Hospital:
“Development of adoptive T-cell therapies in patients with
Her2/over-expressing breast cancer”. The identification of
HER2-specific T-cell receptors (TCR) derived from T cells of
patients with long-lasting specific T-cell immunity and the
potential clinical response will provide the basis for the deve-
lopment of future treatment modalities with the objective of
reaching a broader patient population while reducing costs.
Project management: Dr. med. Angela Krackhardt
Project team at the Regensburg University Hospital:
“Adoptive transfer of CD4+CD25+ regulatory T cells for tole-
rance induction”. Graft-versus-host disease (GVHD) is a major
complication after allogeneic stem cell transplantation (SCT)
and is the main cause of its high treatment-related morbidity
and mortality. We previously demonstrated that the adopti-
ve transfer of donor-derived natural CD4+CD25+Foxp3+
regulatory T cells (Treg) does not induce GVHD in murine
disease models, but prevents GVHD induced by conventional
T cells. We now aim to extend these translational studies to
establish GMP-compatible in vitro expansion protocols for
human Treg cells and to perform a phase I-II dose-finding
and efficacy study in stem cell recipients.
Project management: Professor Dr. med. Matthias Edinger
Project team at the Würzburg University Hospital:
“Development of an immunotherapy protocol for the pre-
vention and treatment of Aspergillus fumigatus infection”.
Mice can be protected from a lethal A. fumigatus challenge
by transfer of Th1 T-cells, by DC vaccination as well as by
induction of Treg T cells. Our group has identified in human
immunodominant A. fumigatus derived T-cell epitopes as
well as an A.fumigatus derived protein, which can condition
DCs for better inflammatory response.
Project management: Dr. med. Max Topp
CONTACT
BayImmuNet
c/o Regensburg University Hospital
Franz-Josef-Strauß-Allee 11
D-93053 Regensburg
Scientific Director:
Prof. Dr. Reinhard Andreesen
Phone: +49 (0)941-9 44-55 01
Fax: +49 (0)941-9 44-55 02
E-Mail: [email protected]
Managing Director:
Dr. Isolde Schäfer
Phone: +49 (0)941-9 44-53 401
Fax: +49 (0)941-9 44-53 42
E-Mail: [email protected]
Internet: www.bayimmunet.de
26
The Bavarian State Ministry of Science, Research and the
Arts is funding a research network with focus on adult neural
stem cells ForNeuroCell (www.bayfor.org/forneurocell).
In ForNeuroCell, groups of the University of Regensburg, the
Helmholtz Center Munich – National Research Center for
Environment and Health, the Friedrich-Alexander-University
of Erlangen-Nuremberg, the Ludwig-Maximlians-University
Munich and the Technical University of Munich work together
on the following research topics.
Reprogramming of neural progenitor cells:
Development of a methodology to differentiate human
astrocytes into functional neurons
Characterizing and establishing of adult human neural
stem cells and identification of signaling pathways and
receptor structures that may serve as targets to modulate
neural stem cells:
Characterization of adult stem cells of the human
hippocampus
Identification of signaling-pathways regulating adult
neural stem cell maintenance
Identification of signaling pathways in the induction,
differentiation and maintenance of dopaminergic neurons
in the embryonic and adult mibrain
Characterization and mobilization of adult neural stem
cells to induce cellular regeneration in Parkinson’s disease
Co-transplantation of adult neural progenitor cells and
mesenchymal stromal cells to promote axonal
regeneration und remyelination in the injured spinal cord
Establishing and implementing innovative imaging techni-
ques to detect endogenous neurogenesis and grafted cells:
In vivo cell tracking by magnetic resonance tomography
(MRT) of adult neural stem cells and brain parenchyma
response to stem cell transplantation
Optical and MR imaging tools to track neural stem and
precursor cells in adult brain
ForNeuroCell –research on adult neural stem cells
Neurodegenerative diseases of the brain are among the greatest therapeutic socio-economic challenges to modern industria-
lized societies. The discovery of multipotent neural stem cells within the adult brain has generated great hope in finding ways
to use the regenerative potential of these cells to develop novel therapeutic strategies for neurodegenerative diseases as well
as traumatic injuries of the spinal cord or the head.
27
CONTACT
ForNeuroCell
Physiological Institute
Physiologic Genomics
Dr. Rosi Lederer
Pettenkoferstr.12
D-80336 Munich
Phone: +49 (0)89-2180 75258
+49 (0)89-3187 3864
Fax: +49 (0)89-2180 75216
E-Mail: [email protected],
Figure 1:Adult hippocampal stem cells. Figure (1) shows the dentate gyrus. Stem cells arelocated in a narrow stripe of cells between the granule cell layer (GL) and thehilus. This area is called the subgranular zone (SGZ). Adult hippocampal stemcells exhibit astrocytic properties and are characterized by nuclear expression ofthe transcription factor Sox2 (in red) and glial fibrillary acidic protein (GFAP, ingreen) which is present in the typical radial process of stem cells. Non stem cellastrocytes also express SOX2 and GFAP but lack the characteristic radial process,spanning the granule layer. Exemplary stem cells (white arrow head) are shown inhigher magnification in the inset.
Figure 2:Immature neurons. Adult hippocampal stem cells have the unique capability to give rise tonew granule neurons. Figure (2) shows immature neurons, called neuroblasts. These cellsare characterized by their expression of the microtubuli associated protein Doublecortin(DCX, in green). The expression of the transcription-factor SOX2 (in red) is down-regulatedin neuroblasts. During their further differentiation into mature granule neurons, neurob-lasts stop to proliferate and become post-mitotic. The whole differentiation process of ahippocampal stem cell into a mature granule cell takes about one month.
Pre-clinical testing in acuteand chronic lesion models
This consortium is highly suitable for working on these
questions as the following technological resources are
well established:
state-of-the-art molecular biology
innovative cell biology
pre-clinical animal models
current imaging technologies
availability of human biomaterial
ForNeuroCell aims at advancing basic research on biotech-
nological development of adult stem cells of the nervous
system in order to achieve recovery of damaged brain
regions.
A series of damages occur in the genetic information of all body cells during ageing. Therefore the complex process of on-going
tissue regeneration breaks down. This eventually leads to degeneration – the progressive loss of function of individual organs or
of the overall organism. Typical degenerative diseases in the skeletal and musculoskeletal system are osteoporosis and osteopo-
rosis related fractures, as well as osteoarthrosis, intervertebral disc deterioration and degeneration of tendons. Direct costs of
more than € 36 billion accrue for this disease in Germany annually, which corresponds to approximately 16% of the overall costs
for diseases in the Federal Republic of Germany. Due to ever-increasing life-expectancy, all experts anticipate a considerable
increase in the aforementioned degenerative diseases and their respective related costs.
Platform 2: Cell Application/Cell-tracking
Improvement in the application of stem cells into defect
sites using new injectable systems and carrier materials
Tracking of the introduced stem cells and cell-seeded con-
structs by means of complex cell-tracking in vivo with the
aid of image guided procedures such as nuclear imaging
techniques, magnetic resonance tomography and optical
procedures
Quantitative and qualitative monitoring of the applied cells
is the decisive precondition for an assessment of the inno-
vative forms of innovative stem cell-based therapeutic stra-
tegies
Platform 3: Bio-evaluation/genetically modified large animal
models
Production of genetically modified, immuno-deficient pigs
as model organisms using innovative techniques of gene
transfer
Examination of the efficiency and safety of therapeutic
approaches on the basis of human cells or tissue constructs
in the large animal model
Use of the pig model for pre-clinical evaluation studies
Economic Applications:
Enterprises should evolve out of the three platforms, which test
and evaluate new therapy concepts from the molecular level to
animal models. Following this, their final goal is to commercially
offer these new treatment regimes for degenerative dise-
ases in the aged. Furthermore, detection and eva-
luation of new targets is possible for pharma-
ceuticals supporting the healing of mus-
culoskeletal diseases. This can also be
marketed through early integration
with large industrial enterprises.
28
ForZebRA –New Stem Cell Research for the agedcell-based regeneration of the musculoskeletal system
Indeed, many advances have been made in the treatment of
degenerative diseases, such as the development of artificial
joints or the implementation of drug therapy for osteoporosis.
However, none of the currently used therapeutic procedures
have been able to rectify damage within the tissue; rather
they can merely limit it. In the Research Cooperation
ForZebRA the expertise of nine university partners and twelve
industrial partners is consolidated, in order to examine in
detail degenerative diseases such as osteoporosis, osteoarthri-
tis and tendinopathies in the aged, and to develop innovative
therapeutic strategies, such as stem cell-based therapies.
ForZebRA is divided thematically into three platforms: cell-bio-
logy/genomics, cell-application/cell-tracking and bio-evalua-
tion/genetically modified large animal models. This wide
range of contents and methods allows a detailed analysis of
both degenerative processes and the induction of regenera-
tion during ageing. Concurrently, monitoring of new therapy
concepts can be conducted effectively. The particular point of
scientific interest is the special situation in old patients.
Research Topics
Platform 1: Cell Biology/Genomics
Development of a data-bank for the comparative represen-
tation of the transcriptome of younger, healthier mesenchy-
mal stem cells (MSC) and aged MSCs for detection of key
genetic degenerative diseases and induction of regenera-
tion for the aged
Development of procedures for the inspection of stem cell
quality, and avoidance of ageing in the utilized stem cells
by means of modulation of the gene expression
Examination of changes in the gene expression after
mechanical manipulation of cells and tissues
Partners
Academic Partners:
Clinic of the LMU Munich, Surgical Clinic and Poly-Clinic-
“Innenstadt”, Experimental Surgery and Regenerative
Medicine (ExperiMed)
Clinic of the LMU Munich, Clinic and Poly-Clinic for Nuclear
Medicine – “Innenstadt” and “Grosshadern”
Forschungszentrum Magnet-Resonanz-Bayern e.V. (MRB)
and University of Würzburg, Physical Institute, Experimental
Physics 5
Gene Centre of the LMU Munich, Chair for Molecular Animal
Husbandry and Bio-Technology and Laboratory for
Functional Genome Analysis (LAFUGA)
LMU Munich, Department Pharmacy, Pharmaceutical
Technology and Bio-Pharmacy
Paracelsus University Salzburg and BG Trauma surgery,
Murnau
TU Munich, Scientific Centre Weihenstephan, Chair for Bio-
Technology of Animals
University of Ulm, Institute for Trauma Surgery Research and
Bio-Mechanics
University of Würzburg, Orthopaedic Clinic in König-Ludwig-
Haus, Orthopaedic Centre for Musculoskeletal Research
Industrial Partners:
Arthrex GmbH, Karlsfeld
BIONORICA AG, Neumarkt
BioStemTec, Munich
Coriolis Pharma, Munich
LivImplant, Munich
MWM Biomodels, Tiefenbach
Novartis Deutschland GmbH, Nuremberg
PolyMaterials AG, Kaufbeuren
PreSens GmbH, Regensburg
Rapid Biomedical, Rimpar
Siemens Medical Solutions AG, Erlangen
Tutogen Medical GmbH, Neunkirchen am Brand
29
CONTACT
Spokesperson: Prof. Dr. med. Wolf Mutschler; Surgical Clinic
and Poly-Clinic-“Innenstadt”, Clinic of the University of Munich
Assistant Spokesperson: Prof. Dr. med. Franz Jakob;
Orthopaedic Centre for Musculoskeletal Research, Chair for
Orthopaedics and Orthopaedic Clinic in König-Ludwig-Haus
Managing Director: Dr. rer. nat. Sabine Ott; Surgical Clinic and
Poly-Clinic-“Innenstadt”, Clinic of the University of Munich
Nußbaumstr. 20
D-80336 Munich
Phone: +49 (0)89-5160-7557
Fax: +49 (0)89-5160-5482
E-Mail:
Internet: www.bayfor.org/forzebra
Investigation of new therapies for degenerative diseases of bone, cartilage and tendon
Funded by the Bavarian Research Foundation with 1.77 m €. Total amount of3.50 m €.
CoNtACt
Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Martinsried
Phone: +49 (0)89-700 656 70
Internet: www.izb-online.de
CoNtACt
BioPark regensburg GmbH
Dr. thomas Diefenthal
Josef-Engert-Str. 9
D 93053 regensburg
Phone: +49 (0)941 920 460
Fax: +49 (0)941 920 4624
Internet: www.bioregio-regensburg.de
CoNtACt
IGZ BioMed/ZmK
Dr. Gerald Böhm
Friedrich-Bergius-ring 15
D-97076 Würzburg
Phone: +49 (0)931 270 62 94
Internet: www.igz.wuerzburg.de
Biotech Incubators in Bavaria